Search Medical Condition
Please enter condition
Please choose location from dropdown

Ankylosing Spondylitis Clinical Trials

A listing of Ankylosing Spondylitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (54) clinical trials

An Observational Study to Evaluate Safety and Efficacy of Remsima in Patients With Ankylosing Spondylitis

The primary objective of this study is to assess the safety of Remsima in ankylosing spondylitis (AS) patients, in comparison with patients receiving other anti-TNF drugs, by evaluation of events of special interest (ESI) for up to 5 years from the first visit of each patient. In order to assess ...

Phase N/A

Progression of Spinal Fusion in Ankylosing Spondylitis

Spinal fusion is the clinical, radiological, and pathological hallmark of ankylosing spondylitis (AS). However, spinal fusion occurs slowly in AS. Serial radiographs rarely show changes over 2 years, and often 5 or more years are needed to demonstrate progression of spinal fusion. Methods that are more sensitive to changes in ...

Phase N/A

A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)

The objectives of this prospective observational study is to explore 1-year clinical response via both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) after initiation of adalimumab therapy in AS patients from routine clinical practices in Taiwan.

Phase N/A

Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA

The general prevalence of spondyloarthritis (SpA) is 0.5% of the Caucasian population and that of ankylosing spondylitis (AS) is 0.3% in France. First-line treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) is insufficiently effective in more than half of AS patients in hospitals. These patients are then treated with "anti-tumor necrosis factor ...

Phase N/A

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.

Phase

Sequential Application of Yisaipu and DMARDs in Treating Mild-to-Moderate AS

The drug regimes in treating ankylosing spondylitis(AS) have limitations. The tumor necrosis factor inhibitors(TNFi) was effective but expensive. Disease modifying anti-rheumatic drugs (DMARDs) were cheap but insufficient. This study proposed a sequential usage of TNFi, the Yisaipu, and DMARDs, and aims to evaluate the mid-term therapeutic effect of this new ...

Phase

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

The purpose of this study is to demonstrate the impact of secukinumab on progression of structural damage in the spine, as measured by the mSASSS in patients with AS.

Phase

The Norwegian Drug Monitoring Study

Infliximab and other TNF-inhibitors have revolutionised the treatment of several immunological inflammatory diseases. Still, more than half of the patients either do not respond sufficiently to infliximab therapy or loose efficacy over time. The large individual variation in the serum drug concentrations on standard doses and the development of anti-drug ...

Phase N/A

One-year Persistence to Treatment of Participants Receiving Flixabi: a French Cohort Study

A study to describe the one-year persistence (participants still treated by Flixabi at 12 Months) in participants treated by Flixabi (infliximab) as prescribed by the physician for each of the 5 following indications: Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Crohn's Disease (CD) [adults and children] and Ulcerative ...

Phase N/A

Treat-to-target With Secukinumab in Axial Spondyloarthritis

Comparison of reductions in MRI inflammation in the sacroiliac joints and spine from week 16 to 24 in patients who at week 16 are in ASDAS remission (i.e. continue sc. secukinumab 150 mg monthly) vs. not in ASDAS remission (i.e. increase sc. secukinumab 300 mg monthly). ASDAS remission is defined ...

Phase